This public procurement contract involves the ongoing supply of a medicinal product containing the active ingredient denosumab at a strength of 120MG, intended for oncology indications (ATC M05BX04). The specific product is denosumab in the form of a 120MG injection solution, packaged as 1X1ML. The
Contract awarded. Originally published 1 years ago.
This public procurement contract involves the ongoing supply of the medicinal product containing the active substance nirsevimab (ATC J06BD08). The specific products required include: - LL-nirsevimab, 50MG injection solution, packaged as 1x0.5ML + 2 syringes - LL-nirsevimab, 100MG injection solution
This public procurement contract involves the ongoing supply of a medicinal product containing the active substance nusinersen (ATC M09AX07). The specific product is LL-nusinersen, in the form of a 2MG injection solution packaged as 1X5ML. The total quantity required is 200 units. This contract is i
This public procurement contract involves the ongoing supply of the medication Sevoflurane (ATC N01AB08), which is a 100% liquid for inhalation. The required quantity is 4,800 units, each in a 250ml container. Additionally, the contract includes the free loan of compatible vaporizers that must work
This public procurement contract involves the delivery and complete implementation of software and hardware solutions for multi-factor authentication (MFA) and single sign-on (SSO). The contract also includes the provision of ongoing support, which will be covered by a separate service agreement. Th
Supply non-clinical consumables including forms, labels, and packaging for pathology and primary care services.
Procurement of RSV immunisation vaccine products for adult populations, scheduled for 2028.
Procurement for meningococcal ACWY vaccine supply in 2027 from qualified manufacturers or distributors.
Procurement opportunity for MMR vaccine supply with anticipated delivery timeline of 2027.
